Bio-Techne Corp (NASDAQ:TECH) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other research analysts have also commented on the stock. Wells Fargo & Company began coverage on shares of Bio-Techne Corp in a research note on Thursday, July 13th. They issued a “market perform” rating on the stock. Zacks Investment Research upgraded shares of Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $131.00 price objective on the stock in a research note on Thursday, July 6th. TheStreet upgraded shares of Bio-Techne Corp from a “c+” rating to a “b” rating in a research note on Tuesday, May 2nd. Deutsche Bank AG restated a “buy” rating and issued a $122.00 price objective (up from $115.00) on shares of Bio-Techne Corp in a research note on Wednesday, May 3rd. Finally, Citigroup Inc. restated a “buy” rating and issued a $125.00 price objective (up from $115.00) on shares of Bio-Techne Corp in a research note on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Bio-Techne Corp presently has a consensus rating of “Buy” and an average target price of $123.20.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/07/bio-techne-corp-tech-stock-rating-lowered-by-bidaskclub.html.

In other news, Director Charles A. Dinarello sold 5,000 shares of the business’s stock in a transaction dated Wednesday, May 31st. The shares were sold at an average price of $111.37, for a total transaction of $556,850.00. Following the transaction, the director now directly owns 12,473 shares in the company, valued at $1,389,118.01. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 10,300 shares of company stock worth $1,146,707. 2.70% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of TECH. Israel Discount Bank of New York purchased a new position in shares of Bio-Techne Corp during the first quarter worth about $105,000. Flinton Capital Management LLC raised its position in shares of Bio-Techne Corp by 10.0% in the first quarter. Flinton Capital Management LLC now owns 1,056 shares of the biotechnology company’s stock worth $107,000 after buying an additional 96 shares during the period. Meadow Creek Investment Management LLC raised its position in shares of Bio-Techne Corp by 10.0% in the first quarter. Meadow Creek Investment Management LLC now owns 1,452 shares of the biotechnology company’s stock worth $148,000 after buying an additional 132 shares during the period. LS Investment Advisors LLC raised its position in shares of Bio-Techne Corp by 49.9% in the first quarter. LS Investment Advisors LLC now owns 1,712 shares of the biotechnology company’s stock worth $174,000 after buying an additional 570 shares during the period. Finally, Glen Harbor Capital Management LLC raised its position in shares of Bio-Techne Corp by 10.0% in the first quarter. Glen Harbor Capital Management LLC now owns 1,848 shares of the biotechnology company’s stock worth $188,000 after buying an additional 168 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Bio-Techne Corp

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Analyst Recommendations for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.